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 Intra-individual variation in the 24-h uptake of iodine by the thyroid is examined.
 For euthyroid adult subjects, a between-days difference of 20% is concluded.
 This inherent variation decreases the precision of relative RAIU data.
 A critical effect size (CES/BMR) of 20% is proposed for benchmark dose analysis.
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A B S T R A C T
Potential adverse effects of chemical substances on thyroid function are usually examined by measuring
serum levels of thyroid-related hormones. Instead, recent risk assessments for thyroid-active chemicals
have focussed on iodine uptake inhibition, an upstream event that by itself is not necessarily adverse.
Establishing the extent of uptake inhibition that can be considered de minimis, the chosen benchmark
response (BMR), is therefore critical. The BMR values selected by two international advisory bodies were
5% and 50%, a difference that had correspondingly large impacts on the estimated risks and health-based
guidance values that were established. Potential treatment-related inhibition of thyroidal iodine uptake
is usually determined by comparing thyroidal uptake of radioactive iodine (RAIU) during treatment with
a single pre-treatment RAIU value. In the present study it is demonstrated that the physiological intra-
individual variation in iodine uptake is much larger than 5%. Consequently, in-treatment RAIU values,
expressed as a percentage of the pre-treatment value, have an inherent variation, that needs to be
considered when conducting dose-response analyses. Based on statistical and biological considerations,
a BMR of 20% is proposed for benchmark dose analysis of human thyroidal iodine uptake data, to take the
inherent variation in relative RAIU data into account. Implications for the tolerated daily intakes for
perchlorate and chlorate, recently established by the European Food Safety Authority (EFSA), are
discussed.
ã 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
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Measurement of the uptake of radioactive iodine as a diagnostic
tool for thyroid function testing (RAIU test) was introduced in the
ﬁfties of the previous century (Astwood and Stanley, 1947;
Goodwin et al., 1951; Greer, 1951). As reliable methods for* Corresponding author.
E-mail address: weterings.peter@gmail.com (P.J.J.M. Weterings).
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0378-4274/ã 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open accmeasuring thyroid hormones became available the diagnostic
use of the RAIU test declined, but in recent years the test has been
employed for examining the potential adverse effects of chemical
substances on the human thyroid (Braverman et al., 2005, 2006;
Greer et al., 2002; Hunault et al., 2007; Kunii et al., 2016; Lawrence
et al., 2001, 2000). In the RAIU test, a quantity of radioactive iodide,
usually sodium 131I-, 132I- or 123I-iodide, is administered orally. At a
speciﬁc time after administration, the fraction of the radioactivity
absorbed by the thyroid is determined by measuring the locallyess article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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(Becker et al., 1996).
The normal range of values for the 24-h iodine uptake in
euthyroid subjects is usually deﬁned as 10–30% but may be as large
as 15–50% in certain parts of the world (Becker et al., 1996;
Franklyn and Shephard, 2000). In the Greer et al. study, the range of
24-h RAIU values before treatment was 9.8–33.7% (Greer et al.,
2002). The rather large normal range has implications for studies
into the potential effects of a chemical substance on the thyroidal
iodine uptake in humans, because it reduces the discriminating
power of a dose-response study with a standard design (several
treatment groups and a control group). That is, the relatively large
inter-individual variability in iodine uptake makes it difﬁcult to
distinguish a change in RAIU due to exposure to a substance when
comparing group average values of exposed and unexposed
subjects.
To account for the impact of inter-individual variability in RAIU
in the human population, several researchers have used study
designs in which subjects served as their own controls and where
the effect measure is the change in RAIU value during exposure to a
substance relative to the subject’s pre-study value (Greer et al.,
2002; Lawrence et al., 2001; Lawrence et al., 2000). However, this
procedure does not account for intra-individual variability and
implicitly assumes that the subject’s pre-treatment value is
constant during the study, and ignores the normal day-to-day
variation in thyroidal iodine uptake. This omission becomes critical
if the calculated relative differences are used for deriving a
tolerable daily intake level for a substance, employing benchmark
dose (BMD) analysis.
BMD analysis is recommended by regulators and other
scientists to assist the determination of, or to establish acceptable
limits for, exposure for chemical substances (Crump, 1984; EFSA,
2009; U.S. EPA, 2012). A BMD analysis essentially involves ﬁtting a
dose-response curve to the observed study data (often obtained at
higher doses and response levels than would be desired in the
human population) and then using the mathematical function
describing that curve to predict the dose or level of exposure that
would be associated with a minimum level of a physiological
response considered adverse. The minimum level of a physiologi-
cally adverse response (e.g., a level of iodine uptake inhibition, a
change in body weight, a change in the serum concentration of a
hormone) is termed the benchmark response (BMR). Proper
selection of a BMR is critical to the BMD analysis; the BMR must be
a meaningful change, both in terms of statistics (is the degree of
change described by the BMR distinguishable from background?)
and biology (is the degree of change meaningful in terms of being
on the margin of something physiologically adverse?).
BMD analysis was conducted for assessing the health risk of
exposure to perchlorate by the Joint FAO/WHO Expert Committee
on Food Additives (JECFA) in 2011 (FAO and WHO, 2011) and more
recently by the Panel on Contaminants in the Food Chain
(CONTAM) of the European Food Safety Authority (EFSA, 2014).
Both expert groups established a tolerable daily intake (TDI) for
perchlorate using data on thyroidal iodine uptake inhibition
determined in the Greer et al. human volunteer study. JECFA
selected a BMR of 50% for the inhibition of thyroidal iodine uptake,
because this level of inhibition was not associated with changes in
the levels of thyroid hormones or TSH following short-term and
chronic exposure of healthy adults to perchlorate (Greer et al.,
2002; Lamm et al., 1999; Lawrence et al., 2000; NAS, 2005). In
contrast, the CONTAM panel posited that chronic adaptive changes
in the thyroid to compensate for a sustained inhibition of the
uptake of iodine could lead to thyroid disease, in particular in
mildly to moderately iodine deﬁcient people, even if thyroid
function tests show no effect following short-term exposure to
inhibitors. Based on this hypothesis, the EFSA panel selected 5%inhibition of the iodine uptake as the BMR in their BMD analysis of
the Greer et al. data. The CONTAM panel also argued that 5% is the
default BMR value applied for continuous data, although EFSA’s
guidance describes this default value in the context of animal
studies, and indicates that health-endpoint-speciﬁc BMR values
may be used based on statistical or toxicological considerations
(EFSA, 2009). Largely because of this difference in BMR, the
tolerable daily intakes established by JECFA and EFSA are different:
10 mg/kg bw/day versus 0.3 mg/kg bw/day, respectively.
Use of a default BMR value of 5% for change in RAIU does not
appear consistent with the known variation in this parameter.
Variation in RAIU measurement attributable to experimental
errors is estimated to be 5% (Francois et al., 1958; Gomez Crespo
and Vetter, 1966), but repeated measurements in euthyroid
subjects (Francois et al., 1958; Hare and Haigh, 1955; Levy et al.,
1959) revealed much larger differences between measurements in
the same person. Francois et al. calculated a standard deviation of
15.3% for the relative differences of each of four 6-h RAIU
measurements with the mean value of each subject (n = 17). The
authors estimated that the physiological contribution to the
observed intra-individual variation has a standard deviation of
14.4%, suggesting biological and/or environmental factors play a
prominent role in the observed day-to-day variation of thyroidal
iodine uptake. Irrespective of the cause of the variability, in order
to decide what level of change is of toxicological relevance, the risk
assessor needs to consider the normal variability for this endpoint
in healthy individuals without known thyroid diseases. More
speciﬁcally, when using the Greer et al. study for establishing a
tolerable intake level for perchlorate, the inherent variation in the
calculated IU inhibition due to the normal intra-individual inter-
day variability in RAIU values in untreated subjects in the study
population should be taken into account.
The present analysis was undertaken with the aim of establish-
ing an appropriate BMR for the benchmark dose analysis of the
inhibition of thyroidal iodine uptake in humans, in particular as
determined in the Greer et al. study.
2. Materials and methods
Literature searches were conducted via MEDLINE (PubMed),
and by searches on the Internet; the latest one in March 2016.
Literature was selected primarily on the basis of the combinations
of search terms ‘thyroid’, ‘RAIU’, ‘radioactive’, ‘iodine/iodide’ and
‘variations’ in the title or abstract. Publications cited in the selected
articles were reviewed if considered appropriate. Only publica-
tions containing individual level RAIU data were included in the
analysis. If data were only presented in graphical form, GetData
Graph Digitizer (www.getdata-graph-digitizer.com) was used to
retrieve data values. In the Greer et al. study, the 8-h and 24-h
uptake of radioactive iodine was determined on several occasions.
Several other studies were identiﬁed, in which 24-h radioactive
iodine uptake was repeatedly measured in the same subjects,
whereas no other repeated 8-h RAIU measurements were found in
the literature. For this reason, we concentrated our analysis on
available 24-h RAIU data.
As outlined in the introduction, in the Greer et al. study the
effect of perchlorate on the thyroidal uptake of iodine was analysed
by expressing RAIU values measured during treatment as a
percentage of the pre-study RAIU value. To be consistent with
this approach, we also analysed the untreated RAIU data obtained
via the literature search using this approach, i.e., taking the ﬁrst
measurement collected as the baseline value:
jfirst measure  second measurej
first measure
 100
Fig. 1. Pooled results of four studies (Greer et al., 2002; Hare and Haigh, 1955;
Lambers et al., 2000; Levy et al., 1959) in healthy euthyroid adults assessing intra-
individual variability in iodine uptake (n = 100).
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absolute difference of the measurements to the second measure
as well as the average of the two measurements. In cases where
more than two measurements were collected, we calculated the
maximum and minimum relative percent difference in RAIU values
among the available measurements and then averaged the
minimum and maximum results to produce one percent relative
difference for each subject. Calculations were made in Microsoft
Excel 2010.
Once an equivalent measure of variability in RAIU was obtained
for each study, we pooled data from the various studies in order to
calculate estimates of percentiles of RAIU variability as well as 95%
conﬁdence intervals (CIs) of estimates. We calculated estimates of
the 1st, 5th, 10th, 25th, 50th, 75th, 90th, 95th, and 99th percentiles
of the distribution of all measures of intra-individual RAIU
variability and 95% conﬁdence intervals for each estimate using
the UNIVARIATE procedure in SAS version 9.3 (SAS Institute; Cary,
North Carolina). This procedure calculates percentiles and CIs non-
parametrically; that is, the method does not include an assumption
of normality or any other distributional form. In addition, the
procedure calculates coverage probabilities of each conﬁdence
interval. The nominal 95% CIs for estimated percentiles typically
represent approximately 95% conﬁdence that the true value falls
within (“is covered by”) the upper and lower bounds; however, 95%
CIs for the percentiles near high and low extremes of a distribution
may cover far less than 95% conﬁdence on account of sparseness of
observations in the tails.
3. Results
In addition to data from the study by Greer et al. (2002), three
other studies were identiﬁed which provided individual level data
on 24-h RAIU variability. Levy et al. (1959) studied the variation in
iodine uptake on two subsequent days by taking 24-h RAIU
measurements in 45 euthyroid subjects (Levy et al., 1959). The
graphically presented data reveal a relative intra-individual
difference in thyroidal iodine uptake of 0–83 percent on the
second day. A second study (Hunault et al., 2007; Lambers et al.,
2000) yielded data on a placebo control group of healthy adult
volunteers (n = 10) in a 4-week toxicity study with nitrate; the 24-h
RAIU was measured before and after the treatment period. The
differences between the two measurements in the same volunteer
range between 0 and 117% of the pre-study value. The third study
identiﬁed was aimed at determining repeatability of 24-h RAIU
measurements in 27 euthyroid subjects (Hare and Haigh, 1955).
The authors reported the data of four measurements at weekly
intervals in eight individuals, stating that these data are
representative for the entire study group. The intra-individual
differences between the 2nd, 3rd and 4th RAIU measurement and
the 1st measurement range between 5 and 110%.
An untreated control group was not included in the Greer et al.
study. However, the study authors concluded that the dose group
average RAIU values determined two weeks after the end of
treatment (P15) and the group average pre-treatment RAIU values
(BL) were statistically indistinguishable, indicating complete
recovery from the inhibiting effect of perchlorate. This is consistent
with the very short biological half-life of perchlorate in humans,
approximately 5 h (Tarone et al., 2010). For this reason, it is
considered acceptable to compare the individual 24-h RAIU
measurements taken in all 37 volunteers on those two days of
the study. The absolute difference between the P15 and the BL
value, calculated using the individual RAIU data from the Greer
et al. study (Merrill, 2001), ranges between 0 and 72% of the BL
value.
A considerable daily variation in thyroidal iodine uptake was
also reported in a study in 17 healthy volunteers by Francois et al.(1958). These authors measured the 6-h RAIU on four days in the
course of one week and found that the difference between the
values measured on the 2nd, 3rd and 4th day and the RAIU value of
the ﬁrst day amounted 0–59%. Because this study involved shorter
term measurements it was not used in our overall analysis.
We pooled the data from the four studies with 24-h RAIU data,
resulting in a total sample size of 100 subjects (Fig. 1). The relative
differences in RAIU ranged from 0 to 116.67% of the ﬁrst RAIU
measurement for each subject and had a mean and standard
deviation of 18.58  19.58%. Estimates of percentiles and corre-
sponding 95% CIs are displayed in Table 1. The nominal 95% CIs for
the 1st and 99th percentiles have coverage probabilities far below
95% due to sparse data in the ends of the distribution. The precision
of percentile estimates decreases as the percentile increases above
the median. The 75th percentile of percent difference in RAIU is
estimated to be 21.13% with fairly narrow conﬁdence intervals (95%
CI: 18.22, 39.50), while the 90th and 95th percentiles have much
wider conﬁdence intervals, indicating decreased certainty about
the true value of these percentiles.
4. Discussion
Criteria have been proposed for assessing the reliability of an
estimated benchmark dose (BMD) and its lower 95% conﬁdence
limit (BMDL) for risk assessment, and thus indirectly for the BMR
chosen for the benchmark dose analysis. For instance, EFSA
considers maximum BMD/BMDL and BMDU/BMDL ratios of 5 and
10, respectively, to be acceptable (EFSA, 2009; EFSA, 2015b).
However, due to the ﬁxation of the starting value (baseline value)
at 100% in studies examining effects on thyroidal iodine uptake, the
conﬁdence interval of the BMD is necessarily smaller than for
datasets from studies with an untreated control group. For this
reason, the BMD/BMDL or BMDU/BMDL ratios are inadequate as
reliability measures of the benchmark dose analysis of studies with
this design. For a BMR to be an indication of adversity of a change in
a physiological parameter, the distribution of the parameter values
in the untreated control group have to be taken into consideration.
The default BMR of 5% for continuous data in animal studies
recommended by EFSA was among other things justiﬁed by
referring to a re-analysis of a large number of studies in animals,
which showed that the overall average BMDL05 was close to the
average of previously established NOAELs (EFSA, 2009). U.S. EPA
Table 1
Percentiles of relative differences in RAIU for pooled studies (n = 100 subjects).
Percentile Estimate 95% CI Coverage probability of 95% CIs
1 0 0, 0 55.46
5 0.61 0, 1.96 96.59
10 2.23 0.13, 3.61 95.23
25 4.82 3.71, 9.86 95.13
50 13.05 11.36, 16.80 95.4
75 21.13 18.22, 39.50 95.13
90 44.25 34.15, 69.30 95.23
95 57 45.00, 116.67 96.59
99 103.25 71.60, 116.67 55.46
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recommended using a change of one standard deviation from the
concurrent control group mean value as the BMR as a default
approach (U.S. EPA, 2012). These approaches for selecting a BMR
have been proposed to account for the between-animal variation in
untreated concurrent control groups. Distributions of the within-
animal variation for biochemical and haematological control data
from 36 studies were used by Dekkers et al. (2006) and Buist et al.
(2009) for deriving BMR values. This approach was based on the
assumption that temporal ﬂuctuations in physiological parameters
in healthy non-exposed animals are non-adverse. Nearly a quarter
of the derived BMR-values were 5%, nearly a quarter were
between 6 and 10%, a quarter was 15% or 20%, and nearly 30% of the
BMR-values were 20% of the endpoint’s control group mean value
(Buist et al., 2009).
Our analysis of 24-h RAIU data in euthyroid subjects obtained
from four studies (Greer et al., 2002; Hare and Haigh, 1955;
Lambers et al., 2000; Levy et al.,1959) indicates that either the 75th
percentile or the 90th percentile of the change in iodine uptake
relative to the initial measurement would be the appropriate
measure of the normal day-to-day change. The value at the 75th
percentile is 21% (i.e., 21% change relative to baseline) while that at
the 90th percentile is 44%. The 75th percentile value appears
preferable to the 90th percentile because the 95% lower conﬁdence
interval on the former value (18%) is relatively close to the central
tendency estimate (21%), suggesting the central tendency estimate
is relatively stable. The conﬁdence limits on the 90th percentile are
substantially wider, suggesting less certainty in the central
tendency estimate. It is also the case that a value associated with
75% of the normal range in biological response might be preferable
from a precautionary perspective to a value associated with 90% (or
even 95%) of the variable response. So as not to suggest too much
precision in the estimates, the 75th percentile value could be
rounded to a 20% change in iodine uptake relative to baseline as the
normal day-to-day change in thyroidal iodine uptake. Consequent-
ly, a difference in RAIU, if measured in the same subject during
exposure to an iodine uptake inhibitor, cannot be attributed to the
inhibitor unless the difference with the pre-treatment value is
more than 20%. To compensate for the inherent variability in the
RAIU values during treatment, if expressed as a percentage of the
pre-treatment value, it is proposed using this value as the BMR for
benchmark dose analysis. Lower BMR values unavoidably result in
biologically unreasonable benchmark dose levels.
In the scientiﬁc opinion on the risks to public health related to
the presence of perchlorate in food, the EFSA CONTAM Panel
selected a BMR of 5% to protect individuals in the population
having a slight to moderate iodine deﬁciency (EFSA, 2014). The
chronic iodine status in a population is inversely correlated with
the avidity of the thyroid gland for iodine (Franklyn and Shephard,
2000; Keeling and Williams, 1972), but it is unlikely that the day-
to-day variation in thyroidal iodine uptake is inﬂuenced by the
long-term iodine status of a population. More likely, the observed
large day-to-day variation in thyroidal iodine uptake is caused bydaily variations in e.g. the diet, due to variable contents of iodine
and (pre)goitrogenic substances (Grayson, 1960). Daily variability
in iodine uptake in the mildly to moderately iodine-deﬁcient
population is therefore unlikely to be different from the similar
variation we observed in four different studies (Greer et al., 2002;
Hare and Haigh, 1955; Lambers et al., 2000; Levy et al., 1959). It
may be that a prolonged marginal inhibition of thyroidal iodine
uptake could potentially be adverse in the mildly to moderately
iodine-deﬁcient population as hypothesized by the EFSA CONTAM
Panel (EFSA, 2014). In its opinion, the CONTAM Panel pointed out
that other mechanisms than the hypothalamus-pituitary-thyroid
feedback mechanism are available to the thyroid to compensate for
a deﬁciency in iodine. The Panel argued that mild to moderate
iodine deﬁciency can lead to the development of goitre and toxic
multinodular goitre (TMNG). The underlying mechanism sug-
gested by the CONTAM Panel is a combination of increased cellular
proliferation (leading to thyroid growth) and an up-regulation of
the production of intracellular hydrogen peroxide, bringing about
an increased mutation rate, eventually leading to the autono-
mously functioning thyroid nodules that are characteristic for
TMNG. The CONTAM Panel further postulated that exposure to
substances interfering with the uptake of iodine at the sodium-
iodine symporter (NIS) might aggravate the iodine status in the
mildly to moderately iodine-deﬁcient population leading to an
increased prevalence of TMNG. Referring to JECFA’s conclusion that
prolonged 50% inhibition of thyroidal iodine uptake is without
adverse effect, the EFSA CONTAM Panel suggested that this degree
of inhibition may lead to goitre and TMNG, even if thyroid function
is not changed during short-term exposure. We believe there are
several weaknesses in the postulated mechanism. First, the
hypothesis is based on epidemiological studies among smoking
and non-smoking subjects in a mildly to moderately iodine-
deﬁcient population. In one of these studies (Knudsen et al., 2002),
it was estimated that approximately 50% of goitre was attributable
to smoking, but thiocyanate, the putative NIS inhibiting chemical
originating from tobacco smoke, was not quantiﬁed. However, the
CONTAM Panel assumed that smokers in this population had
around 50% inhibition of thyroidal NIS, referring to another study
(Laurberg et al., 2004), in which smoking was on average
associated with a 50% decrease in the iodine content of breast
milk. Thiocyanate was proposed by the authors as the cause of the
lower breast milk iodine content, because blood levels of
thiocyanate were higher in smokers than in non-smokers.
However, an inverse correlation between perchlorate (a stronger
inhibitor of iodine uptake than thiocyanate) and iodine in breast
milk of lactating women was not found in four other studies
(Dasgupta et al., 2008; Kirk et al., 2005; Leung et al., 2012; Pearce
et al., 2007), which makes iodine uptake inhibition as the primary
cause of the smoking-related increase in goitre less credible.
Secondly, the assumed absence of changes in short-term
thyroid function tests is contradicted by the ﬁnding in recent
large epidemiological studies that smoking is associated with a
slight decrease in serum TSH and a slight increase in thyroid
hormone levels, both in iodine-sufﬁcient and iodine-deﬁcient
populations (Wiersinga, 2013). Which component of tobacco
smoke is causing this small iodine-independent increase of thyroid
hormone levels in smokers is not yet known, but it is unlikely
thiocyanate, because an increase in thyroid hormone levels was
observed after passive exposure to tobacco smoke for as brief as
one hour (Metsios et al., 2007). This effect is opposite to what
would be expected with competitive NIS inhibition and would also
seem to be too short a window to deplete thyroidal iodine stores
and trigger thyroid hormone changes. Tobacco smoke is a complex
mixture, which complicates attributing physiological effects to a
single component or to a single metabolite such as thiocyanate.
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nate and perchlorate may reduce the iodine content of the thyroid
in the mildly to moderately deﬁcient population even further is
based on the positive association between mild iodine deﬁciency
and the prevalence of multinodular goitre in Denmark. However, in
this population, the iodine and selenium status are positively
correlated and selenium deﬁciency has also been found to be
associated with an increased prevalence of multinodular goitre
(Rasmussen et al., 2011). In a population-based prospective cohort
study in Germany, smoking was still positively associated with
goitre in older subjects (60 years, with pre-existing goitre) after
salt iodination, whereas in younger subjects (<40 years) an inverse
association was found between smoking and the prevalence of
goitre (Ittermann et al., 2008). This study shows that not only
iodine deﬁciency but goitre is a pre-requisite for progression of the
thyroid disease by smoking. These observations and studies render
the suggested linear pathway from goitrogen-mediated iodine
uptake inhibition to the aggravation of (toxic) multinodular goitre
less probable. The observed association between smoking and (T)
MNG in the mildly to moderately iodine-deﬁcient population may
be caused by components in tobacco smoke other than thiocya-
nate, and the underlying mechanism is probably more complex
than merely inhibition of iodine uptake.
The cells of the thyroid also appear capable of managing short-
term variations in iodine uptake and its metabolic consequences
without adverse effects. In groups of mice, carrying a lacZ reporter
plasmid, maintained on low iodine diets (intermediate and
deﬁcient) during one year, mild goitre developed after a few
weeks, accompanied with decreased thyroid hormone but
unchanged TSH. At 8 weeks and 3 months, antioxidant gene
expression was increased, while the maximum expression of the
TSH receptor gene and mRNA for NIS and thyroid peroxidase was
measured at one year. The activation of antioxidant genes point at
increased oxidative stress, probably caused by increased intracel-
lular hydrogen peroxide. Increased thyroid DNA modiﬁcations
were observed after 8 weeks (only examined in rats on an iodine-
deﬁcient diet). However, the mutation rate, which is much higher
in thyroid cells than in other cell types, was unchanged, both in
mice fed with the moderately iodine-deﬁcient diet and in mice on
the iodine-deﬁcient diet. Apparently, the additional decrease in
iodine intake was without any effect on the mutation rate (Maier
et al., 2007). Human thyroid cells required much higher concen-
trations of hydrogen peroxide than T cells to induce detectable DNA
damage, and cells survived radiation doses causing double-strand
breaks (Versteyhe et al., 2013). These ﬁndings suggest that thyroid
cells are particularly resilient against the effects of increased
oxidative stress, such as brought about by a shortage of iodine,
through up-regulation of anti-oxidant and glutathione peroxidase
genes.
Summarising, the suggested role of thiocyanate in the associa-
tion between increased prevalence of multinodular goitre and
smoking in the mildly to moderately iodine-deﬁcient population is
unproven. The resilience of thyroid cells to oxidative stress and the
stability of the mutation frequency under conditions of increasing
iodine deﬁciency in the study by Maier et al. suggests that a slight
inhibition of thyroidal iodine uptake in excess of the inhibition
caused by mild to moderate iodine-deﬁciency is tolerated,
providing a biological basis for a critical effect size larger than 5%.
However, our main argument against a BMR of 5% in benchmark
dose analysis of relative RAIU data for human health risk
assessment is of a statistical nature. Our analysis shows that the
discriminative power of the study design does not allow a change
smaller than 20% to be observed in the relative RAIU data. Thus, to
take account of the inherent variation in secondary (relative) RAIU
data, we propose selecting a BMR of 20% in the dose-response
modelling of such data for deriving a tolerable daily intake.It is reasonable to ask about the implications of slight goitrogen-
associated changes in RAIU for a population of individuals even if
these changes are within the range of temporal variation for the
individual. We are familiar with such arguments being made in the
past, notably with respect to lead and intelligence quotient (IQ). In
the case of lead and IQ, it was argued that even non-clinically
relevant changes in IQ at the individual level in response to lead
exposure could be signiﬁcant at the population level, particularly
with respect to individuals in the ‘tails’ of the population response
curve (Schmidt, 2013). Yet the situation with thyroid perturbation
is fundamentally different. A decrease in IQ is an adverse outcome
whereas a change in iodide uptake is not necessarily so. More
importantly, IQ is understood to be an essentially ﬁxed parameter
and the only variation in measured IQ is due to limitations of the
testing instrument. In contrast, as we have shown here, RAIU is
highly variable over time and the normal temporal variation for a
single individual accounts for a larger part of the measured value
than the limits of the relevant test. Thus accounting for this intra-
individual temporal variation in dose-response analysis is appro-
priate. Ideally that would be done by taking a large number of pre-
exposure measurements in each subject to characterize that
variability and testing the experimental results against that
characterized baseline accordingly. However, the existing data
were not obtained in this way and, in our analysis we attempt to
correct for this deﬁciency.
5. Conclusions
We conclude that the inherent variability of the dataset should
be taken into account when conducting benchmark dose analysis
with secondary RAIU data from studies without a concurrent
control group. In view of the normal intra-individual variability, a
critical effect size (BMR) of 20% is considered most appropriate for
benchmark dose analysis of these data.
In the case of perchlorate, using PROAST benchmark dose
analysis software (see supplementary documentation), the result-
ing BMDL20 is 16.6 mg/kg bw/day. Applying the assessment factor
of 4, derived by the EFSA CONTAM panel to allow for interhuman
differences in toxicokinetics (EFSA, 2014), leads to a TDI for
perchlorate of 4 mg/kg bw/day. The TDI for chlorate, established by
EFSA (EFSA, 2015a), is derived from the TDI for perchlorate and
consequently may also need to be re-considered.
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